KR20240051953A - Pi3k 이소형 알파를 억제하는 화합물 및 암 치료 방법 - Google Patents
Pi3k 이소형 알파를 억제하는 화합물 및 암 치료 방법 Download PDFInfo
- Publication number
- KR20240051953A KR20240051953A KR1020247007455A KR20247007455A KR20240051953A KR 20240051953 A KR20240051953 A KR 20240051953A KR 1020247007455 A KR1020247007455 A KR 1020247007455A KR 20247007455 A KR20247007455 A KR 20247007455A KR 20240051953 A KR20240051953 A KR 20240051953A
- Authority
- KR
- South Korea
- Prior art keywords
- compound
- pi3kα
- alkyl
- subject
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163231156P | 2021-08-09 | 2021-08-09 | |
| US63/231,156 | 2021-08-09 | ||
| PCT/US2022/039674 WO2023018636A1 (en) | 2021-08-09 | 2022-08-08 | Compounds that inhibit pi3k isoform alpha and methods for treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20240051953A true KR20240051953A (ko) | 2024-04-22 |
Family
ID=83188497
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020247007455A Pending KR20240051953A (ko) | 2021-08-09 | 2022-08-08 | Pi3k 이소형 알파를 억제하는 화합물 및 암 치료 방법 |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US20240343728A1 (https=) |
| EP (1) | EP4363414A1 (https=) |
| JP (1) | JP2024533975A (https=) |
| KR (1) | KR20240051953A (https=) |
| CN (1) | CN118159534A (https=) |
| AU (1) | AU2022325819A1 (https=) |
| CA (1) | CA3227902A1 (https=) |
| CL (1) | CL2024000327A1 (https=) |
| CO (1) | CO2024000448A2 (https=) |
| CR (1) | CR20240045A (https=) |
| DO (1) | DOP2024000019A (https=) |
| EC (1) | ECSP24008488A (https=) |
| GE (1) | GEAP202416449A (https=) |
| IL (1) | IL310588A (https=) |
| JO (1) | JOP20240020A1 (https=) |
| MA (1) | MA63885B1 (https=) |
| MX (1) | MX2024000708A (https=) |
| PE (1) | PE20240652A1 (https=) |
| WO (1) | WO2023018636A1 (https=) |
| ZA (1) | ZA202401094B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202541794A (zh) | 2022-11-02 | 2025-11-01 | 美商佩特拉製藥公司 | 用於治療疾病之磷酸肌醇3-激酶(pi3k)之靶向別位及正位袋點 |
| KR20260005985A (ko) | 2023-05-05 | 2026-01-12 | 일라이 릴리 앤드 캄파니 | Er+ 유방암을 갖는 대상체에서 중추 신경계 (cns) 전이를 치료 및 예방하는 데 사용하기 위한 임루네스트란트 또는 그의 염 |
| WO2025036439A1 (en) * | 2023-08-16 | 2025-02-20 | Laekna Pharmaceutical Ningbo Co., Ltd. | Multicyclic compounds and their use as pi3k alpha inhibitors |
| WO2025144931A1 (en) * | 2023-12-27 | 2025-07-03 | Genesis Therapeutics, Inc. | Methods for treating cancer |
| WO2025201503A1 (en) * | 2024-03-28 | 2025-10-02 | InventisBio Co., Ltd. | Compounds, preparation methods and uses thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0515025D0 (en) * | 2005-07-21 | 2005-08-31 | Novartis Ag | Organic compounds |
| SI2170906T1 (sl) * | 2007-06-26 | 2013-07-31 | Ucb Pharma, S.A. | Zliti derivati tiazola, kot inhibitorji kinaze |
| JP2012521354A (ja) * | 2009-03-20 | 2012-09-13 | アムジエン・インコーポレーテツド | Ｐｉ３キナーゼの阻害薬 |
| DE102009043260A1 (de) * | 2009-09-28 | 2011-04-28 | Merck Patent Gmbh | Pyridinyl-imidazolonderivate |
| WO2011163195A1 (en) * | 2010-06-21 | 2011-12-29 | Incyte Corporation | Fused pyrrole derivatives as pi3k inhibitors |
| HK1232227A1 (zh) * | 2014-07-04 | 2018-01-05 | Lupin Limited | 作为pi3k抑制剂的喹嗪酮衍生物 |
| AU2016287463B2 (en) * | 2015-07-02 | 2020-07-02 | F. Hoffmann-La Roche Ag | Benzoxazepin oxazolidinone compounds and methods of use |
| WO2017221272A1 (en) * | 2016-06-23 | 2017-12-28 | Sun Pharmaceutical Industries Limited | Process for the preparation of idelalisib |
| WO2021001431A1 (en) * | 2019-07-02 | 2021-01-07 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Use of pi3ka-selective inhibitors for treating metastatic disease in patients suffering from pancreatic cancer |
-
2022
- 2022-08-08 US US18/293,823 patent/US20240343728A1/en active Pending
- 2022-08-08 PE PE2024000156A patent/PE20240652A1/es unknown
- 2022-08-08 WO PCT/US2022/039674 patent/WO2023018636A1/en not_active Ceased
- 2022-08-08 KR KR1020247007455A patent/KR20240051953A/ko active Pending
- 2022-08-08 MA MA63885A patent/MA63885B1/fr unknown
- 2022-08-08 JP JP2024506896A patent/JP2024533975A/ja active Pending
- 2022-08-08 MX MX2024000708A patent/MX2024000708A/es unknown
- 2022-08-08 GE GEAP202416449A patent/GEAP202416449A/en unknown
- 2022-08-08 AU AU2022325819A patent/AU2022325819A1/en active Pending
- 2022-08-08 CN CN202280062281.6A patent/CN118159534A/zh active Pending
- 2022-08-08 IL IL310588A patent/IL310588A/en unknown
- 2022-08-08 EP EP22764505.8A patent/EP4363414A1/en active Pending
- 2022-08-08 CR CR20240045A patent/CR20240045A/es unknown
- 2022-08-08 CA CA3227902A patent/CA3227902A1/en active Pending
-
2024
- 2024-01-18 CO CONC2024/0000448A patent/CO2024000448A2/es unknown
- 2024-02-01 EC ECSENADI20248488A patent/ECSP24008488A/es unknown
- 2024-02-01 JO JOJO/P/2024/0020A patent/JOP20240020A1/ar unknown
- 2024-02-02 CL CL2024000327A patent/CL2024000327A1/es unknown
- 2024-02-02 ZA ZA2024/01094A patent/ZA202401094B/en unknown
- 2024-02-02 DO DO2024000019A patent/DOP2024000019A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN118159534A (zh) | 2024-06-07 |
| US20240343728A1 (en) | 2024-10-17 |
| CO2024000448A2 (es) | 2024-02-15 |
| IL310588A (en) | 2024-04-01 |
| MX2024000708A (es) | 2024-02-08 |
| MA63885A1 (fr) | 2024-09-30 |
| MA63885B1 (fr) | 2025-01-31 |
| CL2024000327A1 (es) | 2024-08-09 |
| DOP2024000019A (es) | 2024-03-15 |
| ECSP24008488A (es) | 2024-05-31 |
| JP2024533975A (ja) | 2024-09-18 |
| CA3227902A1 (en) | 2023-02-16 |
| GEAP202416449A (en) | 2024-04-25 |
| CR20240045A (es) | 2024-02-20 |
| AU2022325819A1 (en) | 2024-02-29 |
| EP4363414A1 (en) | 2024-05-08 |
| WO2023018636A1 (en) | 2023-02-16 |
| ZA202401094B (en) | 2025-05-28 |
| PE20240652A1 (es) | 2024-04-04 |
| JOP20240020A1 (ar) | 2024-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11897871B1 (en) | Methods for treating cancer | |
| KR20240051953A (ko) | Pi3k 이소형 알파를 억제하는 화합물 및 암 치료 방법 | |
| CN111053768A (zh) | 用于治疗黑素瘤的药物组合 | |
| WO2015168599A1 (en) | Combination therapies targeting mitochondria for cancer therapy | |
| WO2022094271A1 (en) | Methods for treating cancer | |
| WO2022098992A1 (en) | Use of macrocyclic compounds in methods of treating cancer | |
| WO2022072645A2 (en) | Methods for treating cancer | |
| KR20250075714A (ko) | 암을 치료하는 방법 | |
| WO2023173083A1 (en) | Tetrahydroindole derivatives as egfr and/or her2 inhibtors useful for the treatment of cancer | |
| WO2022197913A1 (en) | Bicyclic derivatives which can be used to treat cancer | |
| WO2022072632A1 (en) | Bicyclic compounds for use in the treatment cancer | |
| EA049995B1 (ru) | Соединения, ингибирующие изоформу альфа pi3k, и способы лечения онкологического заболевания | |
| BR112024002063B1 (pt) | Compostos que inibem isoforma alfa de pi3k, composições que o compreendem, usos dos mesmos, e combinações | |
| HK40107546A (zh) | 抑制PI3K同工型α的化合物和用於治疗癌症的方法 | |
| WO2024254266A1 (en) | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer | |
| WO2024254298A1 (en) | A 1,5-dihydro-4h-pyrrolo[3,2-c] pyridin-4-one for use in the treatment of cancer | |
| US20260125366A1 (en) | Methods for treating cancer | |
| WO2026015745A1 (en) | Macrocyclic ras inhibitors | |
| WO2026015740A1 (en) | Macrocyclic ras inhibitors | |
| HK40128998A (zh) | 治疗癌症的方法 | |
| EA053149B1 (ru) | Производные мочевины, полезные для лечения онкологического заболевания | |
| HK40026870A (en) | A pharmaceutical combination for the treatment of melanoma |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| R18-X000 | Changes to party contact information recorded |
St.27 status event code: A-3-3-R10-R18-oth-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |